Clinical Trials

8 studies in Kidney Transplant

1. Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant Rochester, MN View Summary
   Close

   Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   A strongly positive crossmatch has long been considered an absolute contraindication to kidney transplantation and most patients with anti-HLA antibody never were able to receive a kidney transplant. Over the past decade, significant progress has been made in overcoming early antibody-mediated renal allograft injury. Our group has performed more than 200 such transplants providing the possibility of transplant to previously untransplantable patients. Despite our best efforts, transplantation in these patients is still complicated by a high rate of acute humoral rejection. Patients included in this study will be those who have demonstrable anti-HLA antibody specific for their living donor. It is our hypothesis that blockade of terminal complement activation at the time of transplant in combination with our current protocols will reduce the incidence of AHR in patients with anti-donor HLA antibody.

   NCT ID:

   NCT00670774

   IRB Number:

   07-007208

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Nong Yowe Braaten, LPN 507-538-9617
                       
   
   
   

2. The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates Rochester, MN View Summary
   Close

   The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The study is designed to assess the impact of in vivo treatment of bortezomib on anti-HLA production by normal antibody secreting cells (ASC) in sensitized renal allograft candidates. The design involves in vivo treatment with bortezomib for one 4 dose cycle (days 1, 4, 8 and 11). Using novel assays, anti-HLA production is determined by bone marrow derived ASC at baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib dose). Paired data are used with patients serving as their own controls. Finally, the safety of bortezomib is evaluated by monitoring total serum antibody levels and the incidence of side effects (primarily neuropathy) at 1 month, the final follow-up point.

   NCT ID:

   NCT00722722

   IRB Number:

   08-000556

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Nong Yowe Braaten 507-538-9617
                       
   
   
   

3. Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation Rochester, MN View Summary
   Close

   Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Kidney transplantation is considered the best therapy for patients with end-stage renal disease. In some instances, the only suitable living kidney donor is ABO blood group incompatible. This usually presents a barrier to successful transplantation because most recipients have circulating serum antibodies that bind to incompatible blood groups that will bind and damage the kidney allograft early after transplantation. Fortunately, over the past decade, we and others have developed protocols involving the pretransplant removal of anti-blood group antibodies using multiple plasmapheresis treatments that allow for the successful transplantation of ABOi LDKTx. Thus, this therapy enables patients to receive a living donor with its advantages rather than having to wait >5 years for a deceased donor kidney.

   NCT ID:

   NCT01095887

   IRB Number:

   09-003392

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Nong Yowe Braaten, LPN 507-538-9617
                       
   
   
   

4. Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients Rochester, MN View Summary
   Close

   Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The aim of this risk protocol is to determine the variability of the AlloElispot and Allospecificities assay. Our group has developed two novel assays to determine: 1) the number of donor-specific alloantibody (DSA) secreting bone marrow derived plasma cells (AlloELISPOT assay); and 2) the function of DSA-secreting Plasma cells (Allospecificities assay). These assays were developed over the past 3 years and already have provided an important means of testing new therapeutic protocols aimed at controlling DSA production. It is important to note that repeated attempts to isolate PCs from peripheral blood have been unsuccessful (PCs are extremely rare in peripheral blood) and the bone marrow is the only accessible source of PCs. It is now clear to that we have reached a point that we must validate these assays (coefficient of variation, etc), in order to appropriately evaluate data derived from these assays. Inter-assay variability can be assessed by performing two paired assays in the same patient. This could be done in two ways—paired bone marrow aspirations separated by time or two bone marrow aspirations performed at the same time. We have decided to pursue the latter approach. We will do both marrows either at the time of transplantation when the subjects are under general anesthesia or in the Clinical Research Unit (CRU) using conscious sedation.. We believe that this is safe and will be well-tolerated and will provide the data that we need to validate the assays.

   NCT ID:

   NCT01150487

   IRB Number:

   10-002572

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Cindy Groettum 507-266-8725
                       
   
   
   

5. Serial Blood and Urine Monitoring Study in Kidney Transplant Recipients Scottsdale and Phoenix, AZ View Summary
   Close

   Serial Blood and Urine Monitoring Study in Kidney Transplant Recipients

   Location:

   Scottsdale and Phoenix, AZ

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it working for a long time. One field of interest is how one's cellular make-up might affect the body's immune response (body's natural defense system to illness and foreign things) to a kidney transplant. Cellular tests, like gene expression, help doctors to study a person's cellular traits. Gene expression is when information found in one's DNA is translated into RNA and eventually proteins. These components are present in each of the body's cells. In this study, researchers are trying to learn if certain changes in the RNA and proteins found in blood, urine, or transplant biopsy tissue can detect rejection before injury can occur or become too severe. The blood and urine tests will look for patterns in one's DNA (called genetic markers). This study will follow subjects for 2 years after transplant. There will be a total of 12 study visits with additional study visits if rejection occurs. The study requires additional samples of blood, urine, and tissue to be collected during routine clinical visits and biopsies (a procedure to remove and examine a small piece of kidney tissue).

   NCT ID:

   NCT01289717

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   
   Scottsdale: Raymond Heilman, MD
                       Michael Leonard
   
   

6. Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation Rochester, MN View Summary
   Close

   Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   The purpose of this study is to see if the study drug bortezomib will prevent transplant glomerulopathy in patients who are at a high risk of developing the condition due to high donor-specific alloantibody in post kidney transplant recipients.

   NCT ID:

   NCT01349595

   IRB Number:

   10-001487

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Nong Yowe Braaten, LPN 507-538-9617
                       
   
   
   

7. Validation of Gene Expression Markers of Renal Allograft Functional Decline Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN View Summary
   Close

   Validation of Gene Expression Markers of Renal Allograft Functional Decline

   Location:

   Jacksonville, FL Scottsdale and Phoenix, AZ Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Researchers would like to see if it is possible to predict which transplanted kidneys will do better long term based on the gene expression within a kidney biopsy one year after transplant. Gene expression profiling is used to study the activity of genes. Each gene has an "on/off" switch that controls how they are expressed in a cell, as well as a "volume control" that increases or decreases the level of expression of a particular gene as necessary. Researchers want to see if the presence and abundance of certain transcripts in a kidney biopsy at one year after transplant can predict which kidneys will have reduced function over time.

   NCT ID:

   NCT01782586

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Cindy Groettum 507-266-8725
                       
   Scottsdale: Michael Leonard 480-342-2908
                       
   Jacksonville: Dana Kontras 904-953-2325
                       
   

8. A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients Scottsdale and Phoenix, AZ View Summary
   Close

   A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

   Location:

   Scottsdale and Phoenix, AZ

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Subjects will be followed for 6 months. Upon completion of the first 6 months of the study, subjects may participate in the Long Term Extension period of the study. Subjects will remain on their original treatment arm up to three years post-transplant (and / or Sponsor discontinues development or the subject no longer wishes to participate in the study).

   NCT ID:

   NCT01780844

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   - Mayo Clinic Cancer Center - Phone: 507-538-7623 - Research Volunteer Program - Phone: 1-800-664-4542 (toll-free) Email: clinicaltrials@mayo.edu - International Research - Phone: 507-284-8884 Email: intl.mcr@mayo.edu